Regenerative medicine uses clinical procedures to repair or replace damaged or diseased tissues and organs, versus some traditional therapies that just treat symptoms.
To realize the vast potential of tissue engineering and other techniques aimed at repairing damaged or diseased tissues and organs, the University of Pittsburgh School of Medicine and UPMC established the McGowan Institute for Regenerative Medicine. The McGowan Institute serves as a single base of operations for the University’s leading scientists and clinical faculty working to develop tissue engineering, cellular therapies, and artificial and biohybrid organ devices.
The McGowan Institute is the most ambitious regenerative program in the nation, coupling biology, clinical science, and engineering. Success in our mission will impact patients’ lives, bring economic benefit, serve to train the next generation of researchers, and advance the expertise of our faculty in the basic sciences, engineering, and clinical sciences. Our efforts proudly build upon the pioneering achievements of the Thomas E. Starzl Transplantation Institute.
While there are certain select therapies based on regenerative medicine principles now in clinical use, much work lies ahead to realize the potential of this growing field. Advances in the underlying science, engineering strategies to harness this science, and successful commercial activities are all required to bring new therapies to patients.
McGowan Institute for Regenerative Medicine
450 Technology Drive
Pittsburgh, PA 15219
The McGowan Institute sponsors a podcast series on regenerative medicine. Listen to some of the world's leading regenerative medicine researchers and physicians talk about their work.
The McGowan Institute for Regenerative Medicine has been one of the prolific research centers at the University of Pittsburgh over the past 25 years, particularly in terms of its impact from translating discoveries from the lab to the clinic/market. With more than 1,000 invention disclosures submitted, 220 patents issued, and 203 licenses executed, including 34 spinout companies, the approximately 250 McGowan Institute-affiliated faculty and their students have established a track record for commercial translation unrivaled at Pitt.
ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced that the Food and Drug Administration (FDA) has granted the company De Novo clearance for the Hemolung Respiratory Assist System. This system was developed at the McGowan Institute for Regenerative Medicine by a team of researchers led by faculty member William Federspiel, PhD, the company’s cofounder and professor of bioengineering, chemical engineering, critical care medicine, and the Clinical Translation Institute at the University of Pittsburgh. Dr. Federspiel is also the director of the Medical Devices Laboratory at the McGowan Institute.
As we age, our muscles gradually become smaller, weaker, and less able to heal after injury. In a new study, University of Pittsburgh and UPMC researchers pinpoint an important mediator of youthfulness in mouse muscle, a discovery that could advance muscle regeneration therapies for older people.
During the Magee-Womens Summit, the Magee-Womens Research Institute (MWRI) awarded the $1 million Magee Prize to an international team led by McGowan Institute for Regenerative Medicine affiliated faculty member Pamela Moalli, MD, PhD, director of urogynecology and pelvic reconstruction surgery at UPMC Magee-Womens Hospital and MWRI. The team is working to develop new biomaterials to repair tissue loss in women with compromised vaginal structure and function.